Erica DiNapoli

Erica DiNapoli is an Assistant Editor for OncLive®. She joined the company in 2020 and now assists in editing and publishing both videos and informational articles to the website; she also helps manage the social media platforms. Prior to joining MJH Life Sciences, she was a student at Monmouth University and held two marketing internships at United Teletech Financial Federal Credit Union and Trendsetter Media & Marketing.

Articles

Novel Approaches Lead the Charge Away from Chemoimmunotherapy in CLL

October 14th 2020

Matthew S. Davids, MD, MMSc, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia and ongoing research in the space.

Relugolix Continues to Showcase Encouraging Efficacy, Safety in Advanced Prostate Cancer

October 13th 2020

Neal D. Shore, MD, FACS, spotlights relugolix, a novel, gonadotropin-releasing hormone antagonist, that shows great promise in the advanced prostate cancer armamentarium.

Family History Plays Key Role in Germline Testing for Hereditary Breast and Ovarian Cancers

October 12th 2020

Sofia D. Merajver, MD, PhD, discusses the importance of germline testing in patients with breast and ovarian cancer along with how this testing is being used to personalize treatment.

Quadruplet Regimens Seek to Raise the Bar in Frontline Multiple Myeloma

October 12th 2020

Derek Galligan, MD, discusses the role of 3-drug combinations and ongoing research efforts that are focused on evaluating the use of quadruplet regimens earlier on in the treatment journey.

Rapisuwon Reviews Management Approaches for Advanced Noncutaneous Melanoma Subtypes

October 8th 2020

Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.

2020 ISGIO Seeks to Simplify Complexities in GI Cancer to Improve Care

October 3rd 2020

Tanios S. Bekaii-Saab, MD, FACP, shares key topics covered in the 17th Annual ISGIO meeting and its significance in the ever-evolving GI cancer space.

Experts Examine Predictive Value of MRD, Maintenance Strategies in Myeloma

September 30th 2020

Nina Shah, MD, and Sandy Wong, MD, discuss the predictive value of minimal residual disease and a potential course of treatment for a patient with revised International Staging System I multiple myeloma.

Secondary Cytoreduction Plays Role in Recurrent Ovarian Cancer Management, But Selection Is Key

September 29th 2020

Michael Guy, MD, discusses pivotal trials that have helped to define the role of secondary cytoreductive surgery in recurrent ovarian cancer.

PARP Inhibitors Underscore the Need for Routine Germline Testing in Prostate Cancer

September 29th 2020

Ajjai Shivaram Alva, MBBS, discusses the role of PARP inhibitors in prostate cancer, the importance of germline testing, and the need for personalized medicine.

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

September 29th 2020

BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.

Vokes Voices How to Use Genomics to Predict Response to Checkpoint Inhibitors in Cancer

September 26th 2020

Natalie I. U. Vokes, MD, discusses the rise of predictive genomic biomarkers in oncology.

Novel Combos With Belantamab Mafodotin May Move the Needle in Myeloma

September 24th 2020

Sagar Lonial, MD, FACP, discusses the approval of belantamab mafodotin-blmf and how it addressed an unmet need in relapsed/refractory multiple myeloma.

Ibrutinib Plus Short‐Course Fludarabine Elicits Encouraging CR Rates in Previously Untreated CLL

September 23rd 2020

Christopher Pleyer, MD, discusses the phase 2 trial examining fludarabine plus ibrutinib in CLL and SLL, the next steps for the research, and where future efforts should be focused.

Venetoclax Raises the Bar in Newly Diagnosed AML Ineligible for Intensive Chemotherapy

September 17th 2020

Catherine Lai, MD, MPH, discusses the significance of venetoclax in the acute myeloid leukemia treatment paradigm, the data from the VIALE-A trial, and remaining challenges faced in practice.

Quadruplets Poised to Become New Standard in Frontline Transplant-Eligible Myeloma

September 17th 2020

Susan Bal, MD, discusses key trials in the multiple myeloma space.

Novel Agents Rouse Responses in Relapsed/Refractory Multiple Myeloma

September 16th 2020

Thomas G. Martin, MD, discusses the importance of targeted therapy in multiple myeloma, in addition to ongoing research.

Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies

September 11th 2020

Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.

Sekeres Sheds Light on Promising Activity With Pevonedistat/Azacitidine in Higher-Risk MDS, Low-Blast AML

September 9th 2020

Mikkael A. Sekeres, MD, highlights findings from a phase 2 study that evaluated the combination of pevonedistat and azacitidine in higher-risk MDS, CML, and LB AML, and the next steps for research.

Balzarotti Breaks Down New Developments in the Expanding DLBCL Paradigm

September 9th 2020

Monica Balzarotti, MD, discusses the current treatment landscape of DLBCL, including the recent FDA approval of selinexor for the treatment of adult patients with relapsed/refractory disease.

Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma

September 8th 2020

Marc J. Braunstein, MD, PhD, highlights pivotal research on the use of triplet and quadruplet regimens in the up-front and relapsed/refractory multiple myeloma treatment settings presented during the 2020 ASCO Virtual Scientific Program.